Erratum to: Ephrin receptor A2 is an epithelial cell receptor for Epstein–Barr virus entry (Nature Microbiology, (2018), 3, 2, (164-171), 10.1038/s41564-017-0080-8);Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry

Nature Microbiology

Volumn 3, Issue 2, 2018, Pages 164-171

  Zhang, Hua ^a   Li, Yan ^a   Wang, Hong Bo ^b   Zhang, Ao ^a   Chen, Mei Ling ^a   Fang, Zhi Xin ^a   Dong, Xiao Dong ^a   Li, Shi Bing ^a   Du, Yong ^a   Xiong, Dan ^a   He, Jiang Yi ^a   Li, Man Zhi ^a   Liu, Yan Min ^a   Zhou, Ai Jun ^a   Zhong, Qian ^a   Zeng, Yi Xin ^a   Kieff, Elliott ^c   Zhang, Zhiqiang ^d,e   Gewurz, Benjamin E ^c   Zhao, Bo ^b,c   Zeng, Mu Sheng ^a   more..

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIMETHYLPYRROLYL BENZOIC ACID; BENZOIC ACID DERIVATIVE; EPHRIN RECEPTOR A1; EPHRIN RECEPTOR A2; UNCLASSIFIED DRUG; 2,5-DIMETHYLPYRROLYLBENZOIC ACID; BENZOIC ACID; CHAPERONE; EPHRIN A2; GLYCOPROTEIN L, HUMAN HERPESVIRUS 4; MEMBRANE PROTEIN; VIRAL PROTEIN;

ARTICLE; CONTROLLED STUDY; CRISPR-CAS9 SYSTEM; EPSTEIN BARR VIRUS; FIBRONECTIN TYPE III DOMAIN; HUMAN HERPESVIRUS 8; LIMIT OF QUANTITATION; MICROARRAY ANALYSIS; NONHUMAN; NPE CELL LINE (NASOPHARYNGEAL); PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; VIRUS CELL INTERACTION; VIRUS ENTRY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHO CELL LINE; CRICETULUS; CRISPR CAS SYSTEM; DRUG EFFECT; EPITHELIUM CELL; GENE KNOCKDOWN; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; PATHOGENICITY; VIROLOGY;

ANIMALS; BENZOATES; CHO CELLS; CRICETULUS; CRISPR-CAS SYSTEMS; EPHRIN-A2; EPITHELIAL CELLS; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HERPESVIRUS 4, HUMAN; HUMANS; MEMBRANE GLYCOPROTEINS; MOLECULAR CHAPERONES; RECEPTOR, EPHA2; RNA INTERFERENCE; VIRAL PROTEINS; VIRUS INTERNALIZATION;

EID: 85039797270     PISSN: None     EISSN: 20585276     Source Type: Journal    
DOI: 10.1038/s41564-018-0155-1     Document Type: Erratum

References (33)

1. Lieberman, P. M. Virology. Epstein-Barr virus turns 50. Science 343, 1323-1325 (2014).
2. Hutt-Fletcher, L. M. Epstein-Barr virus entry. J. Virol. 81, 7825-7832 (2007).
3. Wang, H. B. et al. Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells. Nat. Commun. 6, 6240 (2015).
4. Hahn, A. S. et al. The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma-associated herpesvirus. Nat. Med. 18, 961-966 (2012).
5. Thorley-Lawson, D. A., Hawkins, J. B., Tracy, S. I. & Shapiro, M. The pathogenesis of Epstein-Barr virus persistent infection. Curr. Opin. Virol. 3, 227-232 (2013).
6. Shannon-Lowe, C. & Rowe, M. Epstein Barr virus entry; kissing and conjugation. Curr. Opin. Virol. 4, 78-84 (2014).
7. Ogembo, J. G. et al. Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor. Cell Rep. 3, 371-385 (2013).
8. Wang, X., Kenyon, W. J., Li, Q., Mullberg, J. & Hutt-Fletcher, L. M. Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells. J. Virol. 72, 5552-5558 (1998).
9. Turk, S. M., Jiang, R., Chesnokova, L. S. & Hutt-Fletcher, L. M. Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells. J. Virol. 80, 9628-9633 (2006).
10. Kirschner, A. N., Omerovic, J., Popov, B., Longnecker, R. & Jardetzky, T. S. Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion. J. Virol. 80, 9444-9454 (2006).
11. Borza, C. M. & Hutt-Fletcher, L. M. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat. Med. 8, 594-599 (2002).
12. Chesnokova, L. S. & Hutt-Fletcher, L. M. Fusion of Epstein-Barr virus with epithelial cells can be triggered by ? v? 5 in addition to ? v? 6 and ? v? 8, and integrin binding triggers a conformational change in glycoproteins gHgL. J. Virol. 85, 13214-13223 (2011).
13. Chesnokova, L. S., Nishimura, S. L. & Hutt-Fletcher, L. M. Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins ? v? 6 or ? v? 8. Proc. Natl Acad. Sci. USA 106, 20464-20469 (2009).
14. Xiong, D. et al. Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells. Proc. Natl Acad. Sci. USA 112, 11036-11041 (2015).
15. Chakraborty, S., Veettil, M. V., Bottero, V. & Chandran, B. Kaposi's sarcoma-associated herpesvirus interacts with EphrinA2 receptor to amplify signaling essential for productive infection. Proc. Natl Acad. Sci. USA 109, E1163-E1172 (2012).
16. Wykosky, J. & Debinski, W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol. Cancer Res. 6, 1795-1806 (2008).
17. Hahn, A. S. & Desrosiers, R. C. Binding of the Kaposi's sarcoma-associated herpesvirus to the ephrin binding surface of the EphA2 receptor and its inhibition by a small molecule. J. Virol. 88, 8724-8734 (2014).
18. Valencia, S. M. & Hutt-Fletcher, L. M. Important but differential roles for actin in trafficking of Epstein-Barr virus in B cells and epithelial cells. J. Virol. 86, 2-10 (2012).
19. Garcia, N. J., Chen, J. & Longnecker, R. Modulation of Epstein-Barr virus glycoprotein B (gB) fusion activity by the gB cytoplasmic tail domain. mBio 4, e00571-00512 (2013).
20. Hafner, C. et al. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin. Chem. 50, 490-499 (2004).
21. Pasquale, E. B. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133, 38-52 (2008).
22. Shao, Z., Zhang, W. F., Chen, X. M. & Shang, Z. J. Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcome. Oral Oncol. 44, 1110-1117 (2008).
23. Rivera, R. S. et al. Involvement of EphA2 in head and neck squamous cell carcinoma: mRNA expression, loss of heterozygosity and immunohistochemical studies. Oncol. Rep. 19, 1079-1084 (2008).
24. Huang, J. et al. EphA2 promotes epithelial-mesenchymal transition through the Wnt/?-catenin pathway in gastric cancer cells. Oncogene 33, 2737-2747 (2014).
25. Tan, P. et al. EphA2 silencing in nasopharyngeal carcinoma leads to decreased proliferation, invasion and increased sensitization to paclitaxel. Oncol. Lett. 4, 429-434 (2012).
26. Chandran, B. Early events in Kaposi's sarcoma-associated herpesvirus infection of target cells. J. Virol. 84, 2188-2199 (2010).
27. Breuss, J. M. et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J. Cell Sci. 108, 2241-2251 (1995).
28. Sheppard, D. Functions of pulmonary epithelial integrins: from development to disease. Physiol. Rev. 83, 673-686 (2003).
29. Ruegg, C. & Mariotti, A. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol. Life Sci. 60, 1135-1157 (2003).
30. Weis, S. M. & Cheresh, D. A. ? V integrins in angiogenesis and cancer. Cold Spring Harb. Perspect Med. 1, a006478 (2011).
31. Song, L. B. et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 66, 6225-6232 (2006).
32. Yan, M. et al. IKK? restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation. Nat. Commun. 5, 3661 (2014).
33. Lung, H. L. et al. TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Res. 66, 9385-9392 (2006).